戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lung metastasis via the sustained release of Zileuton.
2 guinea pig in vivo models and was similar to zileuton.
3 logy, which were absent in mice treated with zileuton.
4 anti-PlGF Ab or the 5-lipoxygenase inhibitor zileuton.
5                            Administration of zileuton 1 day before infection and through day 5 after
6 ebo), and no patients treated with 600 mg of zileuton, 400 mg of zileuton, or placebo, respectively.
7      Patients were randomly assigned to: (a) zileuton 600 mg PO qid, (b) celecoxib 400 mg PO bid, or
8 late (270 and 540 mg/kg), MK-886 (30 mg/kg), Zileuton (600 and 1200 mg/kg), or combinations containin
9  edema model, 40 was more potent than either zileuton (a 5-LO inhibitor) or BN 50739 (a PAF receptor
10 icles (NPs) loaded with photosensitizers and Zileuton (a leukotriene inhibitor) to obtain MPO and neu
11 ercise-induced asthma received either 600 mg zileuton, a 5-lipoxygenase inhibitor, or a placebo four
12 nistration of Manoalide, a PLA2 inhibitor or Zileuton, a 5-LOX inhibitor with VPC reversed the protec
13 looxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileu
14 a deposition in the brains of mice receiving zileuton, a selective and specific 5-LO inhibitor, was s
15                    Coincubation of FMLP with zileuton, a selective inhibitor of 5-lipoxygenase, cause
16  which results in high Hcy, or the Diet plus zileuton, a specific ALOX5 inhibitor, for 7 months.
17                          Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4,
18 susceptible mice with a synthesis inhibitor, zileuton, abrogated allergen absorption and oral anaphyl
19 OX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added to chemotherapy would improve outcome in
20 the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect.
21 on, a selective 5-lipoxygenase inhibitor; or zileuton alone.
22 D-fed wild-type mice with the 5-LO inhibitor Zileuton also results in a reduction of AT macrophages a
23                 These data also suggest that zileuton and anti-PlGF Ab could be promising therapies t
24 nostilbene showed activity comparable to the zileuton and ibuprofen, respectively.
25 e effect of pharmacologic 5-LO inhibition by zileuton and LTB4 inhibition by CP-105,696.
26 ion of endogenous leukotriene synthesis with zileuton and MK-886 dramatically attenuated phagocytosis
27 ranlukast, and the 5-lipoxygenase inhibitor, zileuton, are unique in their ability to target specific
28 elecoxib 400 mg PO bid, or (c) celecoxib and zileuton at the same doses.
29            The results indicate that neither zileuton, Bay x 1005, nor Bay y 1015 inhibited exudate p
30 enes in M1 but less so in M2 macrophages, 3) zileuton blocks resolution-initiating SPM biosynthesis,
31 nhibitors (AA861, nordihydroguaiaretic acid, zileuton) but not a flavoenzyme inhibitor (diphenyleneio
32 ein antagonist MK 886 and the 5-LO inhibitor zileuton, but not by cyclooxygenase inhibitors.
33                                 At 10(-10) M zileuton, cell migration caused by FMLP was decreased by
34 ting 12-LOX (CDC, Baicalein), but not 5-LOX (Zileuton) dose-dependently attenuated tactile allodynia.
35 t (6.1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatm
36 ssments significantly improved in the 600-mg zileuton group and not in the placebo group (P=.007 for
37 he average FEV1 improved 15.7% in the 600-mg zileuton group vs 7.7% in the placebo group (P=.006).
38 inutes after the completion of exercise, the zileuton group's FEV1 was 85.76% of the preexercise valu
39 gonist, zafirlukast, and the 5-LO inhibitor, zileuton, improve pulmonary function and decrease daytim
40 ay x 1005 and Bay y 1015, were compared with zileuton in terms of their ability to decrease exudate v
41                        The administration of zileuton inhibited bronchospasm after exercise challenge
42 ned the effects of the leukotriene inhibitor zileuton on clinical features and lung function.
43  the effects of the 5-lipoxygenase inhibitor zileuton on these responses.
44              Thirteen weeks later, Accolate, Zileuton (only the high concentration), and combinations
45           Treatment with 600 mg or 400 mg of zileuton or placebo (each taken four times daily.)
46 also inhibited by pertussis toxin but not by zileuton or WEB 2086.
47 s treated with 600 mg of zileuton, 400 mg of zileuton, or placebo, respectively.
48 200 +/- 3,620 eos/cm resulted after 10(-6) M zileuton (p < 0.001 versus FMLP).
49 d maximally to 1.15 +/- 2.51% after 10(-8) M zileuton (p < 0.02).
50 Furthermore, in vitro studies confirmed that zileuton prevents Abeta formation by modulating gamma-se
51            At week 43, MK-886, Accolate, and Zileuton reduced lung tumor multiplicity by 37.8, 29.5,
52  Treatment with the 5-lipoxygenase inhibitor zileuton reduced postantigen BALF eosinophil count by 68
53 parable efficacy as reported for aspirin and zileuton, respectively.
54 ve abilities to reconstitute phagocytosis in zileuton-treated rat alveolar macrophages and in alveola
55                                              Zileuton treatment did not induce any change in the stea
56  receiving 5-LO-deficient cell transplant or zileuton treatment had prolonged survival, reduced GVHD
57   Five minutes after exercise, the FVC after zileuton was 92.76% of the preexercise value, as compare
58 aximum percent change in baseline FEV1 after zileuton was a 15.58% decrement from the preexercise lev
59 ne pathway inhibitors, Accolate, MK-886, and Zileuton, were evaluated as chemopreventive agents in fe
60 achidonate 5-lipoxygenase (aLOX5) antagonist zileuton, were protected from oral antigen-induced respo
61 ienes were in the range of the approved drug zileuton, which further underlines the biological import
62 the high concentration), and combinations of Zileuton with either Accolate or MK-886 reduced lung tum
63                  This study examined whether zileuton (ZL), a structural analog of hydroxyurea, posse